NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
週六，納斯達克上市公司NuCana plc (NASDAQ:NCNA)在ESMO大會上報告了NuTide:701第2期研究關於NUC-7738與默沙東公司(NYSE:MRK)的Keytruda (pembrolizumab)聯合治療轉移性黑色素瘤患者的最終數據，這些患者對PD-1抑制劑治療產生了耐藥性或復發。
In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy.
在這12名患者的隊列中，大多數患者至少接受過兩種PD-1抑制劑治療。
Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Responses.
12名患者中有9名(75%)實現了疾病控制，其中包括兩名患者實現了部分緩解。
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.
其中一名接受了兩種PD-1抑制劑治療並在最近兩個月內因伊匹利姆單抗加尼伏馬布治療的療效下降而進展的患者，腫瘤體積減少了55%。
Seven of the 12 patients had a progression-free survival time of over five months.
12名患者中有7名的無進展生存時間超過五個月。
Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma. Outcomes in this patient population are very poor, with median progression-free survival of 2-3 months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression-free survival of more than five months."
NuCana的創始人兼首席執行官Hugh Griffith表示：「我們非常激動地分享NUC-7738與pembrolizumab聯合治療PD-1抑制劑耐藥和抗藥黑色素瘤患者的這些數據。這類患者的預後非常糟糕，目前的標準護理方案中位無進展生存期爲2-3個月，因此我們非常鼓舞人心的是，接受這種聯合治療的大多數患者實現了超過五個月的無進展生存。」
In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile.
除了取得這些鼓舞人心的療效信號外，NUC-7738與pembrolizumab聯合治療還具有良好的安全性。
The company says NUC-7738 can sensitize PD-1-resistant tumors to rechallenge with PD-1 inhibitors due to its ability to target multiple aspects of the tumor microenvironment (TME) via the disruption of RNA polyadenylation and subsequent changes to gene expression in cancer cells.
該公司表示NUC-7738能夠通過靶向腫瘤微環境(TME)的RNA多聚腺苷化破壞及癌細胞基因表達變化，使PD-1耐藥腫瘤對PD-1抑制劑再次挑戰產生敏感性。
Data from tumor biopsies obtained before and after NUC-7738-based treatment demonstrated increases in genes related to antigen presentation and T-cell activation.
經過基於NUC-7738治療前後腫瘤活檢數據顯示與抗原呈遞和T細胞激活相關的基因增加。
In August, NuCana discontinued NuTide:323 study following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
八月份，nucana根據NuTide:323研究中的預定初始分析和NuTide:323研究指導委員會的建議，終止了NuTide:323研究。
While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study's primary objective of superior Progression-Free Survival compared to the control arm of 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev) in the final analysis.
儘管存在有利於對照組的預後失衡，但指導委員會認爲NUC-3373與亞葉酸、伊立替康和貝伐單抗（NUFIRI+bev）聯合使用，不太可能實現該研究的主要目標，即在最終分析中較對照組的5-FU、亞葉酸、伊立替康和貝伐單抗（FOLFIRI+bev）具有更優越的無進展生存率。
Price Action: NCNA stock is up 166.50% at $6.62 during the premarket session at last check Monday.
股票類表現：在上週一的最後一次檢查時，NCNA股價在盤前交易中上漲166.50%，報6.62美元。
- EXCLUSIVE: Gauzy To Showcase AI-Powered Driver Assistance System for Safer Commercial Trucks.
- 獨家報道：Gauzy將展示用於更安全商用卡車的人工智能駕駛輔助系統。
譯文內容由第三人軟體翻譯。
